We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TOPG:TASETop Group Software Ltd. Analysis

Data as of 2026-05-24 - not real-time

MYR 0.80

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Top Glove is riding a bullish technical backdrop with the 20‑day SMA (0.77) comfortably above the 50‑day (0.72) and 200‑day (0.64) averages, while the RSI sits at a neutral 57 and volume is on the rise, indicating continued buying interest. However, the MACD histogram has turned negative and the signal line is bearish, suggesting short‑term momentum may be weakening as the price hovers near the $0.70 support level and below the $0.88 resistance. The stock’s volatility is elevated at 51% over the past month, but its beta of –0.19 points to a defensive profile that may cushion broader market swings.
Fundamentally, Top Glove posted a solid 13.7% revenue growth and generated healthy cash flows, yet profitability remains thin with a 3.8% net margin and a modest ROE of 2.8%. The PE ratio of 40 starkly exceeds the industry average of 27.6, and the DCF‑derived fair value of ~MYR1.04 contrasts with the current price of MYR0.80, implying limited upside. Analyst consensus is a “hold” with a median target of MYR0.75, and the modest 0.6% dividend yield, backed by a 27.9% payout ratio, appears sustainable but offers little income attraction.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near technical support with bearish MACD signal
  • High short‑term volatility
  • Increasing trading volume indicating active market participation

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong revenue growth and positive cash flow generation
  • Forward PE compression to ~29.5 suggesting earnings improvement
  • Valuation still above industry norms limiting upside

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Diversified product portfolio and geographic exposure
  • Sustainable dividend policy despite low yield
  • Margin compression and modest ROE tempering growth expectations

Key Metrics & Analysis

Financial Health

Revenue Growth13.70%
Profit Margin3.84%
P/E Ratio40.0
ROE2.85%
ROA0.41%
Debt/Equity18.01
P/B Ratio1.4
Op. Cash FlowMYR459.0M
Free Cash FlowMYR368.7M
Industry P/E27.6

Technical Analysis

TrendBullish
RSI57.1
SupportMYR 0.70
ResistanceMYR 0.88
MA 20MYR 0.77
MA 50MYR 0.72
MA 200MYR 0.64
MACDBearish
VolumeIncreasing
Fear & Greed Index91.61

Valuation

Fair ValueMYR 1.04
Target PriceMYR 0.72
Upside/Downside-9.61%
GradeOvervalued
TypeBlend
Dividend Yield0.60%

Risk Assessment

Beta-0.19
Volatility51.10%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.